Organ, Louise A.
Duggan, Anne-Marie R.
Oballa, Eunice
Taggart, Sarah C.
Simpson, Juliet K.
Kang’ombe, Arthur R.
Braybrooke, Rebecca
Molyneaux, Philip L.
North, Bernard
Karkera, Yakshitha
Leeming, Diana J.
Karsdal, Morten A.
Nanthakumar, Carmel B.
Fahy, William A.
Marshall, Richard P.
Jenkins, R. Gisli
Maher, Toby M. http://orcid.org/0000-0001-7192-9149
Funding for this research was provided by:
Medical Research Council (G0901226)
National Institute for Health Research (CS-2013-13-017)
British Lung Foundation (C17-3)
GlaxoSmithKline (CRT114316)
Article History
Received: 6 February 2019
Accepted: 1 July 2019
First Online: 12 July 2019
Ethics approval and consent to participate
: The PROFILE study is registered on ExternalRef removed (NCT01134822 and NCT01110694). The study was approved by the Royal Free Hospital Research Ethics Committee Ref 10/H0720/12.
: All subjects provided signed informed consent including for publication of all results arising from the PROFILE study.
: WAF, JKS, EO, CBN, ARK are employees and shareholders of GSK. ST, BN, YK and AMD are working on behalf of GSK. TMM has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speaker fees from Apellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB. RGJ has received industry-academic funding from GlaxoSmithKline R&D, Novartis and Biogen Idec and has received consultancy or speaker fees from InterMune, MedImmune, Pulmatrix, Boehringer Ingelheim, and GlaxoSmithKline R&D. MAK and DJL are employees and shareholders of Nordic Biosciences and hold patents relating to neoepitopes.